Gene editing is far from being a safe technique today, because not all modifications that occur in the genome after its application are desired, leading to genetic changes with unpredictable consequences.
Furthermore, due to the limited knowledge of how our genome works, it is not possible to predict all the effects derived from these modifications, nor the interactions that may be triggered between genes after their alteration, which may affect their functionality.
During the Alzheimer’s Association International Conference (AAIC) 2023 in Amsterdam, a group of scientists has reported on the application of the CRISPR gene editing technique in two therapeutic approaches to treat and prevent Alzheimer’s disease.
They reported two innovative CRISPR-based therapeutic approaches for Alzheimer’s disease: one method targets the APOE-e4 gene, a major genetic risk factor for Alzheimer’s, with the aim of mitigating its effects; the other focuses on reducing the production of beta-amyloid, a protein associated with the disease.
Using the CRISPR gene editing technique, researchers have succeeded in modifying the APP gene, which encodes the amyloid precursor protein, whose appearance in brain tissue in the form of amyloid protein plaques (beta-amyloid) is linked to the onset of Alzheimer’s disease. This gene produces different products, some of which are protective (sAPPa), while others, such as beta-amyloid, are associated with the pathology.
In addition, after the gene editing process, a reduction in beta-amyloid plaques in brain tissue was achieved. This led to a decrease in inflammation markers and an increase in the neuroprotective forms of amyloid (sAPPa) and, therefore, an improvement in the functioning of the nervous system and behavior in mice with Alzheimer’s disease.
Although it is too early to think about its application in humans, in the research with mice no significant side effects were detected, which suggests a possible application in humans in the near future.
Dr. Brent Aulston, lead author and postdoctoral fellow at the Altman Clinical and Translational Research Institute at UC San Diego, told Medical News Today that “the idea of our therapeutic is to utilize CRISPR to introduce a change in the patient’s genome that is protective against Alzheimer’s disease.”
“So far, we have tested this approach in mice that have the same disease characteristics as human Alzheimer’s patients and found that our therapy decreases markers of disease. Moreover, no unwanted side effects have been observed,” he said.
“Our CRISPR therapeutic was designed so that it can be applied to all forms of Alzheimer’s disease (i.e. familial and sporadic types). We are currently working on translating this approach from the lab to the clinic with the goal of our CRISPR-based gene therapy being a treatment option for the disease someday.”
In another study, researchers at Duke University developed a potential therapeutic approach using CRISPR to target a genetic risk factor for Alzheimer’s disease called APOE-e4.
Inheriting this gene increases the likelihood of developing Alzheimer’s, as one copy of APOE-e4 increases the risk two- to three-fold and two copies further amplify the risk, approximately eight- to twelve-fold.
The researchers used an epigenomic therapy platform based on the CRISPR/Cas9 editing strategy to reduce APOE-e4 levels. They achieved significant success in miniature brains derived from human induced pluripotent stem cells from an Alzheimer’s patient, as well as in humanized mouse models.
Importantly, this approach did not affect the levels of other APOE variants that are thought to have a neutral or protective effect.
According to Dr. Ornit Chiba-Falek, a professor at the Alzheimer’s Disease Research Center and Center for Genomic and Computational Biology at Duke University Medical Center, “the platform reduces the expression of APOE, the strongest genetic risk factor for Alzheimer’s disease, by closing the genomic region surrounding the gene making it less accessible for the transcriptional machinery”.
This experiment would not involve eliminating or replacing genes, but rather modifying their spatial structure through epigenetic changes that would reduce their capacity for expression and, therefore, for synthesis of the protein responsible for the disease.
Despite the promising results, according to Raymond J. Tesi, MDm CEO and Chief Medical Officer at INmune Bio “Alzheimer’s disease may not be the best place to apply CRISPR at this time”.
“Treating [Alzheimer’s] patients with CRISPR to prevent the formation of additional amyloid is a confusing strategy. As I understand it, CRISPR therapy will stop amyloid production but will not remove amyloid for patients with [Alzheimer’s]. Isn’t the role of amyloid-targeted therapy to remove amyloid from the brain? Does stopping amyloid production have the same benefit as removing amyloid from the brain? I don’t know” he said.
Dr. Tesi noted that “60 percent of [Alzheimer’s] patients express ApoE4. Unfortunately, we don’t know which patients with ApoE4 will develop [the disease]. Furthermore, we don’t understand what ApoE4 does. That is, is ApoE4 associated with a pathology that causes [Alzheimer’s] or is ApoE4 the cause of cognitive decline? In my opinion, additional research must be done to better understand if the impact of ‘silencing’ ApoE4 before we apply it to humans”.
“I believe it is time to expand our efforts beyond the therapeutic strategies of targeting amyloid – we know how well that works. ApoE4 is an interesting target that deserves more study.”
On the other hand, these types of gene therapies are expensive, costing millions of dollars. For example, one of the most innovative therapies currently used, the drug lecanemab, which is a monoclonal antibody, can cost $26,500 a year. Future anti-amyloid therapies based on CRISPR gene editing techniques are likely to be more expensive than these monoclonal antibody-based treatments.
He Jiankui, a controversial researcher, talks about this new therapeutic possibility
According to ABC newspaper, He Jiankui, the creator of the first illegally genetically modified babies, said in an interview that if the authorities gave him permission, he could begin to eradicate Alzheimer’s within two years. It should be remembered that the experiment cost him a prison sentence.
In November 2018, Jiankui announced the use of CRISPR-Cas9 technology to edit the genes of two human embryos in order to create children immune to the virus by altering the CCR5 gene, which is involved in the penetration of the HIV virus into cells. As a result of their experiment, two twin sisters were born in China in October of that year. They are known by their code names, Lulu and Nana. In August 2019, the third girl, Amy, was born.
The experiment violated the ban on germline gene editing in humans due to its lack of safety and the limited level of knowledge available about its possible consequences.
When asked in the above-mentioned interview about the possible consequences of his modification of the gene, which has also been found to be linked to the development of cognitive activity and memory, He Jiankui remained silent and replied, “I am not going to answer that question.”
He later stated that “when I did the experiment I knew nothing about the connection between the CCR5 gene and memory or intelligence, it was purely for HIV prevention.”
Now, He Jiankui has focused on Alzheimer’s research, using an updated version of the Crispr-Cas9 tool called “base editing”. At the present stage his experimentation is carried out on mice and monkeys, and he claims that in two years he would have the technique ready for application in humans.
Bioethical assessment
It is excellent news that gene editing techniques can make progress in the context of neurodegenerative diseases such as Alzheimer’s, which until now have been incurable. Added to the advances in monoclonal antibody therapies that we have mentioned, they open a window of hope for a cure.
However, gene editing is far from being a safe technique today. Firstly, because not all the modifications that occur in the genome after its application are desired. Some occur outside the intended targets, leading to genetic changes with unpredictable consequences.
Secondly, given the limited knowledge of how our genome works, it is not possible to predict all the effects resulting from these modifications. Nor the interactions that may be triggered between genes after their alteration, which may affect their functionality. This appears to be the case of the Chinese scientist Jiankui, who, in addition to the purported effect of immunizing against AIDS, may have caused serious alterations in the development of affected girls and their offspring.
It is true that very positive results have already been obtained in the correction of some genetic defects responsible for certain diseases, but there are also failures that limit their application in humans.
Furthermore, its application in the human germ line, that is, on gametes, zygotes or early embryos, extends these artificially introduced modifications to all cells of the organism. This would multiply the consequences of unwanted (“off target”) changes, since they would affect all the cells of the individual and could lead to a dangerous alteration of the human genetic heritage, with unpredictable consequences.
These are the reasons for the current international moratorium on the use of germline gene editing in humans, which He Jiankui violated and has said he is willing to do again.
Prudence in correctly assessing the benefits and risks of all research and therapeutic interventions is what should set the limits to technological progress. And it should serve to direct it towards the good of the recipients, not just the fame of some researchers who compete to be the first to reach certain scientific milestones.
Julio Tudela
Bioethics Observatory – Institute of Life Sciences
Catholic University of Valencia